Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — 2Q2019 Earnings Presentation
26 slides from Hyphens Pharma International's earnings presentation, Aug 19, 2019
Slide 1: General Announcement: Hyphens Results Briefing 2Q2019
General Announcement::Hyphens Results Briefing 2Q2019 Page 1 of 2 GENERAL ANNOUNCEMENT::HYPHENS RESULTS BRIEFING 2Q2019 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announ
Slide 2: Sponsor contact and attachments
General Announcement::Hyphens Results Briefing 2Q2019 Page 2 of 2 The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +
Slide 3: Hyphens Pharma International Limited Results Briefing 2Q2019
Hyphens Pharma International Limited Results Briefing 2Q2019 HYPHENS PHARMA INTL LTD (SGX: 1J5)
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 5: Corporate Information and Shareholding
CORPORATE INFORMATION Shareholding Public Float3, 19.7% Bloomberg Code HYP:SP Reuters Code 1J5.SI ISIN Code 1J5 Issued Shares (M) 300.43 Executive Market Cap (SG$M) (16 Aug 2019) 60.1 Director², Inomed 14.6% Holding¹, Share Price (SG$) (16 Aug 2019) 0.20 65.4% Average volume 3-mth (‘000) 200.8 52 wk
Slide 6: Key Developments 2Q2019
KEY DEVELOPMENTS 2Q2019
Slide 7: Ocean Health Revamped
OCEAN HEALTH Odsax REVAMPED CELEBRATING The homegrown everyday choice since 1994 for you and your family’s wellbeing. Always your guardian of health empowering you to live life fully. Weare gefing «1 nakeouer | Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group
Slide 8: Ocean Health Revamped (Cont'd)
OCEAN HEALTH REVAMPED (CONT’D)
Slide 9: Atopic Dermatitis Range
ATOPIC DERMATITIS RANGE Gentle Non-Soap Wash Maintenance Therapy Enriched with Essential Skin Lipids in a pH Balanced System * NEW! Specially-Formulated Triple Protective Action Menthol Gel to Calm & Ceramide-Dominant Mosquito Repellent For AD Against Diaper Rash Soothe Itchy Skin Therapeutic Moistu
Slide 10: pH balanced emollient launched this year
LAUNCHED THIS YEAR! An advanced emollient with pH balanced system with a patent pending formulation
Slide 11: Xcelarev launched this year
LAUNCHED THIS YEAR! LIGHTENS 3 DARK SPOTS IN MONTHS1 XCELAREV® A PATENTED DELIVERY SYSTEM2 WELL TOLERATED WITH LONG-TERM USE1 1 Based on data on file 2 Patent No.: UK GB 2549418
Slide 12: Ceradan OTC Drive
CERADAN OTC DRIVE Media PR Launch Event To view more photos, ATTENDEES from please visit our LinkedIn page Media Representatives, Influencers & Buyers rebrand.ly/hyphens
Slide 13: Ceradan OTC Drive (Cont'd)
CERADAN OTC DRIVE (CONT’D) Media PR Launch Event Some of the Mummy Influencers: @weecheryl @fj.mama @deedeedee13 @adebabysuns @bigtreeandkoala @poojakawatra @iamyvetteking and more!
Slide 14: Ceradan OTC Drive (Cont'd)
CERADAN OTC DRIVE (CONT’D) Retail Activities OTC Shelf Displays Exclusive Trade Packs Roadshows @ Guardian
Slide 15: New Specialty Pharma Principals
NEW SPECIALTY PHARMA PRINCIPALS Central Exclusive Vietnam Exclusive Nervous Distributor Distribution System Agreement Vietnam Syntellix Manufactures MAGNEZIX® for Quicker & Safer Bone Recovery Lundbeck Renowned Global MAGNEZIX® is a Pharmaceutical magnesium alloy metallic Company implant that can be
Slide 16: SGX Publications
SGX PUBLICATIONS SGX= meee SINGAPORE’S LEADING SPECIALTY PHARMACEUTICAL AND CONSUMER HEALTHCARE GROUP. i Sktode US BNG-HVPS — AC-HOHS! 10 Questions for Hyphens Pharma International eee mas. Price on 2? Mar (8) 020 ‘Company Overview S2wkhigi ow 0305-0.150 Hyphens Pharma international is @ Singapore-b
Slide 17: RHB Research Reports
RHB RESEARCH REPORTS INVESTMENT BANKING ‘Top Singapore Small Cap Companies 20 Jewels 2019 Edition 3 July 2019 Hyphens Pharma Hye sp) Undervalued And Under-Covered; Initiate BUY Singapore initiating Coverage Healthcare | Pharmaceuticals Buy ‘Tangat Price (Retum) G00 25 (+28%) Pree $000 196 Maret Ca h
Slide 18: Investor-One Stock Pitch Challenge
INVESTOR-ONE STOCK PITCH CHALLENGE
Slide 19: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 20: Income Statement
INCOME STATEMENT S$’000 2Q2019 1Q2019 Change % 1H2019 1H2018 Change % Revenue 29,002 27,004 7.4% 56,006 61,515 -9.0% Gross profit 10,149 9,475 7.1% 19,624 20,710 -5.2% Opex 8,259 7,923 4.2% 16,236 16,504 -1.6% EBITDA 2,526 2,186 15.6% 4,712 4,814 -2.1% Profit before tax 2,040 1,675 21.8% 3,715 4,384
Slide 21: Segment Revenue 1H2019 1H2018
SEGMENT REVENUE 1H2019 1H2018 Medical Hypermart & Digital 19,472; 18,880; 35% 29,470; 31% 35,872; 53% 6,763; 7,064; 58% 11% 12% Proprietary Specialty Pharma Brands Principals Figs in S$’000
Slide 22: Quarter-on-Quarter Revenue
QUARTER-ON-QUARTER REVENUE S$’000 35000 30,628 30,887 30000 29,448 29,967 29,002 27,004 9578 9,301 25000 9,287 10,187 9,730 9,742 20000 3378 3,386 3,089 3,315 3,638 15000 3,426 10000 17672 18,200 17,591 15,946 15,634 13,836 5000 0 1Q2018 2Q2018 3Q2018 4Q2018 1Q2019 2Q2019 Specialty Pharma Principals
Slide 23: Financial Position & Cash Flow
FINANCIAL POSITION & CASH FLOW S$’000 As at 30 Jun 2019 As at 31 Dec 2018 Total assets 74,585 74,979 Cash & cash equivalents 23,646 22,353 Total liabilities 33,950 35,817 Financial liabilities 458 3,000 Total equity 40,635 39,162 NAV per share (cents) 13.53 13.05 S$’000 2Q2019 2Q2018 1H2019 1H2018 C
Slide 24: Financial Ratios
FINANCIAL RATIOS As at 30 Jun 2019 As at 31 Dec 2018 Current ratio 1.96 1.80 Debt-to-Equity ratio 0.84 0.91 ROE 12.5%(1) 13.8% EV/EBITDA 7.5(1)(2) 7.4(2) PE ratio 11.6(1)(2) 10.8(2) PB ratio 1.45(1)(2) 1.49(2) (1) Based on 12-month trailing PAT & EBITDA (2) Based on closing share prices of S$0.196 o
Slide 25: Future Growth
FUTURE GROWTH Establishing a Broader Geographical Footprint Cementing leadership position in Singapore and deepening ASEAN presence Internationalisation of proprietary brands New Product Launches Continue to enhance Driven by Enhanced product offerings Human Capital through licensing and Inves
Slide 26: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — 2Q2019 Earnings Presentation on 6ix